Leinco Technologies

Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-E6) - HRP

Product Code:
 
LEI-LT7092
Product Group:
 
Primary Antibodies
Host Type:
 
Virus
Antibody Isotype:
 
Human IgG1
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
NP1-E6
Regulatory Status:
 
RUO
Target Species:
  • SARS-CoV-2
  • Virus
Application:
 
Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
 
Blue Ice
Storage:
 
This horseradish peroxidase conjugated mon°Clonal antibody is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-LT7092-50ug50 ug£432.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Horseradish Peroxidase (HRPO)
Format:
This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Formulation:
This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Immunogen:
SARS-CoV-2 Nucleocapsid (N) Protein
Long Description:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus belonging to the Coronaviridae family1. The SARS-CoV-2 genome encodes four essential proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. SARS-CoV-2 shares 79.6% identity with the original SARS-CoV2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in a couple of primary functions, including RNA binding and self-oligomerization3,4. This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein5. The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways6,7. The N protein is a suitable candidate for vaccine development and diagnostic assays8 for several reasons. It is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein9. Furthermore, antibodies9,10 and memory T cells11,12 targeting the N protein are identified in the sera of convalescent COVID-19 patients, demonstrating it as immunogenic. The N protein also suppresses antiviral RNAi, evading the innate immune system13, suggesting its potential value as a targeted therapeutic.
NCBI Gene:
43740575
Target:
SARS-CoV-2 Nucleocapsid (N)

References

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270?273. 2020. 2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265?269. 2020. 3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020. 4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006. 5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005. 6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008. 7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010. 8. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020. 9. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020. 10. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020. 11. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020. 12. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020. 13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.